Livmarli patents expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
May, 2031

(7 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(9 years from now)

US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(16 years from now)

US11497745 MIRUM NA
Feb, 2040

(16 years from now)

Livmarli is owned by Mirum.

Livmarli contains Maralixibat Chloride.

Livmarli has a total of 4 drug patents out of which 0 drug patents have expired.

Livmarli was authorised for market use on 29 September, 2021.

Livmarli is available in solution;oral dosage forms.

Livmarli can be used as treatment of cholestatic pruritus in patients with alagille syndrome (algs).

Drug patent challenges can be filed against Livmarli from 2025-09-29.

The generics of Livmarli are possible to be released after 12 February, 2040.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028
New Patient Population (NPP) Mar 13, 2026

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 2025-09-29

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)


More Information on Dosage

LIVMARLI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic